This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Cerus Corporation, Pfizer Corporation, University of California. Active years: 2021-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 76 
1 out of 4,492 
1 out of 16,082 
Years Active: 2021-2024
Title: Tovo David: Innovator in Pathogen-Inactivated Platelet Compositions
Introduction
Tovo David is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of medical technology, particularly in the development of pathogen-inactivated platelet compositions. With a total of 3 patents to his name, David's work has the potential to enhance the safety and efficacy of blood transfusions.
Latest Patents
David's latest patents include innovative methods for preparing pathogen-inactivated platelet compositions. These patents provide detailed methodologies for creating platelet compositions that are safe for transfusion, minimizing the risk of transmitting infections. The processing sets and related compositions outlined in his patents are crucial for advancing medical practices in transfusion medicine.
Career Highlights
Throughout his career, Tovo David has worked with prominent organizations such as Cerus Corporation and the University of California. His experience in these institutions has allowed him to collaborate with leading experts in the field, furthering his research and development efforts.
Collaborations
David has collaborated with several professionals in his field, including Betsy Donnelly and Anna Erickson. These partnerships have contributed to the successful development of his patented technologies and have fostered innovation in the medical community.
Conclusion
Tovo David's contributions to the field of pathogen-inactivated platelet compositions highlight his role as an influential inventor. His patents and collaborations reflect a commitment to improving medical safety and efficacy. David's work continues to impact the field positively, paving the way for future advancements in transfusion medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile